Feed RGEN
RG

Repligen

RGEN · NASDAQ

$181.70 +2.52% (+$4.47)
1M +8.41%
Market Cap $10.0B
P/E Ratio 240.79x
Div. Yield -
ROE 1.98%

Bulios Fair Price

$117.75

35.2% downside

Current Price

$181.7

Undervalued Fair Value Overvalued

According to Bulios Fair Price, RGEN is currently overvalued relative to its market price. How does it work?

Unlock fair price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Strong
7/9
Valuation
5 /100
Expensive
P/S 12.74x
P/E 240.79x
P/B 4.74x
Growth
31 /100
Declining
FCF growth 34.33%
EPS growth 35.73%
Book val. growth 3.30%
Profitability
64 /100
Moderate
Op. margin 8.32%
Gross margin 51.05%
FCF margin 14.11%
Quality
10 /100
Poor
ROA 1.41%
ROIC 1.83%
Asset turnover 0.27x
Debt
86 /100
Low
Int. coverage 3.50x
Debt/Equity 0.33x
Net debt/EBITDA 0.69x
Stability
42 /100
Moderate
EPS volatility 243.31%
Beta 1.05x
Profitable years 1

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RGEN
Online

About the company

Repligen is an American company engaged in the development and production of materials used in the production of biological drugs. Based in Waltham, Massachusetts, the company was incorporated in Delaware in 1981. Repligen is a public company listed on the NASDAQ stock exchange under the symbol RGEN.

Sector

Healthcare

Industry

Medical - Instruments & Supplies

CEO

Olivier Loeillot

Employees

2,000

Headquarters

Waltham

Upcoming events

03 NOV

Earnings

Upcoming earnings report

30d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.